MICROBA-LIFE-SCIENCES
29.11.2022 05:28:41 CET | Business Wire | Press release
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is pleased to announce that leading medical diagnostics provider Sonic Healthcare Limited (ASX: SHL) (“Sonic”) has agreed to invest $17.8m to acquire a 19.99% shareholding in Microba. In addition, Sonic is seeking to acquire options for an additional 5% equity position, subject to shareholder approval. Exercise of the options by Sonic would result in a further investment of $7.5m in Microba.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221128005863/en/
(Photo: Business Wire)
Microba and Sonic have also agreed initial binding terms for a strategic alliance to deliver Microba's microbiome testing technology into Australia, New Zealand, Germany, United Kingdom, Belgium, Switzerland and the United States.
Microba’s Chief Executive Officer, Dr Luke Reid said, “We are excited to have Sonic Healthcare, a global leader in healthcare, become a major strategic shareholder and partner. Sonic is globally respected for its leadership in delivering trusted medical diagnostic services, and our partnership deeply aligns the interests of both companies to bring microbiome testing and therapeutics into the hands of clinicians and patients globally to improve standard of care.
“This strategic partnership with Sonic is set to accelerate international distribution of Microba’s microbiome testing into primary and specialist healthcare, and move our testing deeper into routine patient management.”
Sonic Healthcare’s Chief Executive Officer, Dr Colin Goldschmidt said, “Sonic Healthcare prides itself on delivering accurate, reliable medical diagnostics services using leading laboratory and informatics technologies. Our partnership with Microba exemplifies our commitment to invest in cutting edge developments in laboratory medicine. We see microbiome testing becoming a key part of pathology over coming years and are excited about the potential of this partnership and the opportunities that Microba's technology will provide for Sonic’s global operations, our referring clinicians, and our patients.”
Sonic acquires strategic stake in Microba
Sonic has entered into an equity subscription agreement to acquire a 19.99% stake in Microba, through the issue of new fully paid ordinary shares (Shares), at an issue price of $0.26 per share and representing a 25% premium to the 5-day VWAP of Microba shares ending on the date prior to this announcement, raising $17.8m in new capital for the Company.
The Shares will be issued within Microba's existing placement capacity under ASX Listing Rule 7.1 and 7.1A. Following the issue of these Shares, Sonic will be a substantial shareholder, holding a relevant interest in 19.99% of the issued share capital of Microba.
Furthermore, Sonic seeks to acquire unlisted options exercisable at 33c per share with an expiry of 18 months after the date the Shares are issued. The option exercise price represents a 58% premium to the 5-day VWAP of Microba shares ending on the date prior to this announcement. If exercised, the options would represent a further 5% of the issued share capital in Microba following completion of the share issue and will only be issued subject to receiving shareholder approval for the purpose of ASX Listing Rule 7.1 at a General Meeting, which is expected to be in held in February 2023, the approval of which will be recommended by the Board of Microba. The exercise of the options will be subject to compliance by Sonic with the Corporations Act 2001 (Cth).
Strategic relationship
Microba and Sonic have entered into initial terms of an agreement which enables Sonic Healthcare Limited and its subsidiaries to exclusively distribute Microba’s microbiome testing products to its customers, including general practitioners and specialists, across Germany, Belgium and the United Kingdom for a period of 1 year commencing on 31 January 2023 with the intention to extend subject to finalisation of full license and distribution agreements. The initial agreed terms also provide Sonic Healthcare Limited and its subsidiaries with non-exclusive distribution rights for Switzerland, the United States, Australia and New Zealand.
All license and distribution agreements will accommodate existing Microba service delivery and distribution arrangements. The full license and distribution arrangements are expected to be finalised over the coming months.
Sonic Chief Medical Officer to join Microba’s Medical Advisory Board
With the two companies’ united strategic objectives to bring cutting-edge microbiome testing into routine healthcare, Sonic Healthcare’s Group Chief Medical Officer, Dr Stephen Fairy, will join Microba’s Medical Advisory Board, responsible for governing the medical and scientific direction of Microba’s commercial activities. Dr Fairy will join a high-profile group of medical professionals on Microba’s Medical Advisory Board comprising Prof. Ian Frazer (AC), Prof. Paul Griffin, Prof. Jake Begun and Dr Chris Hogan (OAM). Sonic will not currently seek a position on Microba’s Board of Directors.
About Sonic Healthcare
Sonic Healthcare is one of the world’s leading healthcare providers, with a reputation for excellence in laboratory medicine/pathology, radiology and primary care medical services, across operations in Australasia, Europe and North America. Employing over 41,000 people globally, Sonic is the largest private pathology operator in Australia, Germany, Switzerland and the UK, the second-largest in Belgium and New Zealand and the third-largest in the USA.
About Microba Life Sciences Limited
Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221128005863/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vena Completes Acterys Acquisition to Accelerate Orchestrated Planning for the Microsoft Ecosystem26.3.2026 14:00:00 CET | Press release
The combination connects AI-driven financial and operational planning, analytics and execution across Microsoft Excel and Power BI, removing decision latency for Microsoft-centric enterprises. Vena, the AI-powered Orchestrated Performance Management platform purpose-built to fully amplify the Microsoft technology ecosystem, today announced it has completed its acquisition of Acterys, the leading Microsoft Power BI–based operational planning and app development platform. The move strengthens Vena’s Orchestrated Planning solution and begins phased integration of the two platforms. Modern enterprises are struggling to keep up with the volatility and dynamism of the markets they serve. Market drivers and signals shift rapidly, and the ability to assess, plan and execute with confidence and speed is more important than ever. These forces, combined with overwhelming data density and disparity, have created a new constraint: decision latency—the time between signal and action. As that gap wid
Nearly Half of Global C-Suites Plan U.S. Expansion Within 12 Months, as Supply Chain and Capital Access Drive Growth26.3.2026 14:00:00 CET | Press release
• 45% of C-level executives plan to establish a U.S. legal entity within the next 12 months; a further 27% say they will consider entry within two to three years • 65% cite supply chain or manufacturing efficiency as the primary driver for U.S. expansion • 88% identify federal and state tax reporting as the most burdensome area of U.S. compliance Nearly half (45%) of global C-suite leaders plan to establish a legal entity in the United States within the next 12 months, highlighting continued demand for access to the U.S. market. This finding from the latest research by CSC—the leading provider of global business administration and compliance solutions—demonstrates the U.S. continues to attract investment from around the world, even as companies face an increasingly complex regulatory landscape. CSC surveyed 300 C-level executives at large organizations headquartered in Europe, the U.K., Asia Pacific, and South America to examine global sentiment toward U.S. market entry, including expa
Lone Star Funds Completes Acquisition of Alliance Ground International26.3.2026 13:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has completed the acquisition of Alliance Ground International (“AGI”), a leading North American airport services provider. “We are excited to partner with the AGI management team to drive the business forward,” said Donald Quintin, Chief Executive Officer of Lone Star. “The company has a superior service offering and a track record of success across its integrated operations. We see opportunities to continue to invest in the business and its people to continue to grow its capabilities and ensure it remains best-in-class in delivering for the aviation industry.” “Today marks an important next step for AGI as we move forward in partnership with Lone Star,” said Jared Azcuy, Chief Executive Officer of AGI. “Our commitment to safety, reliability, and operational service excellence remains unchanged. This partnership strengthens our ability to deliver for our airline partners and reinforces that the
Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging26.3.2026 13:30:00 CET | Press release
The Phase 1 study of RLS-1496, the first human trial of a GPX4 (selective glutathione peroxidase 4) modulator, met its primary endpoint and also demonstrated a statistically significant relationship between target engagement and clinical improvement in psoriasis and atopic dermatitis RLS-1496 is a first-in-class disease-modifying mechanism targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases of aging A second study for RLS-1496 – a Phase 1b/2a study in actinic keratosis (precancerous skin lesions) – is underway in the United States, with completion expected later this year Rubedo CEO Frederick Beddingfield, III, MD, PhD, FAAD, to moderate panel on senescence and skin at the Dermatology Innovation Forum (DIF) during the American Academy of Dermatology (AAD) annual meeting on Thursday, March 26, at 1:05 pm MT in Denver Oral presentation of data accepted at the Society for Investigative Dermatology (SID) from May 13-16, 2026, in Chicago Rubedo L
GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe26.3.2026 13:30:00 CET | Press release
COMPASS is one of the largest public‑private partnerships under the European Union’s (EU) Innovative Health Initiative (IHI). The consortium aims to advance early detection and prediction of cardiotoxicity in cancer patients and cancer survivors. The initiative will leverage AI, advanced imaging, biomarkers, and integrated care pathways. GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the IHI. Cardiovascular diseases are rising sharply among cancer patients and survivors, driven both by the increasing prevalence of pre‑existing cardiovascular conditions at diagnosis and by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom